C.R. Bard, Inc. (NYSE:BCR) Stake Decreased by Arizona State Retirement System
Arizona State Retirement System decreased its stake in C.R. Bard, Inc. (NYSE:BCR) by 55.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,950 shares of the medical instruments supplier’s stock after selling 23,268 shares during the period. Arizona State Retirement System’s holdings in C.R. Bard were worth $5,990,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Macquarie Group Ltd. raised its stake in C.R. Bard by 61.1% in the fourth quarter. Macquarie Group Ltd. now owns 5,800 shares of the medical instruments supplier’s stock valued at $1,303,000 after buying an additional 2,200 shares during the last quarter. Creative Planning raised its stake in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the last quarter. Gulf International Bank UK Ltd raised its stake in C.R. Bard by 1.0% in the first quarter. Gulf International Bank UK Ltd now owns 23,124 shares of the medical instruments supplier’s stock valued at $5,747,000 after buying an additional 220 shares during the last quarter. Pennsylvania Trust Co raised its stake in C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in C.R. Bard during the first quarter valued at $596,000. 85.32% of the stock is owned by institutional investors.
Shares of C.R. Bard, Inc. (BCR) opened at 319.75 on Friday. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $323.27. The stock’s 50 day moving average is $319.00 and its 200 day moving average is $283.44. The company has a market capitalization of $23.24 billion, a PE ratio of 41.98 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.54 EPS. On average, equities research analysts anticipate that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio is 13.67%.
Several analysts have recently weighed in on BCR shares. Jefferies Group LLC raised their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a report on Monday, April 24th. Cowen and Company increased their price target on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research note on Monday, April 24th. Morgan Stanley cut shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. BMO Capital Markets cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target on the stock. in a research note on Tuesday, April 25th. Finally, Raymond James Financial, Inc. reissued a “market perform” rating and set a $265.00 price target on shares of C.R. Bard in a research note on Tuesday, April 25th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. C.R. Bard has a consensus rating of “Hold” and a consensus target price of $285.67.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.80% of the stock is owned by corporate insiders.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.